Bioventus マネジメント
マネジメント 基準チェック /44
Bioventusの CEO はRob Claypooleで、 Jan2024年に任命され、 の在任期間は 2.58年です。 の年間総報酬は$ 4.30Mで、 19.2%給与と80.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.2%を直接所有しており、その価値は$ 2.39M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と5.5年です。
主要情報
Rob Claypoole
最高経営責任者
US$4.3m
報酬総額
| CEO給与比率 | 19.17% |
| CEO在任期間 | 2.6yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 3.3yrs |
| 取締役会の平均在任期間 | 5.5yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Aug 06
BVS: Reaffirmed 2026 Sales Outlook Will Support A Higher Share Price
Analysts have raised their price target for Bioventus from $16.00 to $18.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E as key drivers of the change. What’s in the News for Bioventus Bioventus reaffirmed its earnings guidance for the twelve months ending December 31, 2026, maintaining the 2026 financial outlook that was first issued on May 6, 2026.Seeking Alpha • Jul 07
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
Summary Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments. The 2027 Hospital Outpatient Prospective Payment System and ASC proposed rule are key catalysts for BVS's recent stock surge. Read the full article on Seeking Alphaナラティブ更新 • Jun 17
BVS: 2026 Sales Guidance Will Support A Higher Share Price
Analysts maintained their $16.00 price target on Bioventus, noting only minor adjustments to assumptions such as the discount rate, revenue growth outlook, profit margin, and future P/E, which were not significant enough to change their overall valuation view. What's in the News for Bioventus Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, indicating expected net sales in the range of $600 million to $610 million.
ナラティブ更新 • Jun 03
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have maintained their $14.80 price target for Bioventus, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the updated view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million, based on company guidance.ナラティブ更新 • May 19
BVS: Index Inclusion And 2026 Guidance Will Support A Higher Price
Analysts have raised their Bioventus price target from $15.00 to $16.00, citing updated assumptions related to revenue growth, profit margins, discount rates, and future P/E levels. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million and implied growth of about 6% to 7% (company guidance).分析記事 • May 14
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are
Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. Our analysis says...ナラティブ更新 • May 01
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have maintained their Bioventus fair value estimate at $14.80 while making only small adjustments to key inputs such as the discount rate and expected future P/E, indicating fine-tuning of their valuation framework rather than a major change in outlook. What's in the News Bioventus Inc.ナラティブ更新 • Apr 17
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have modestly fine tuned their $14.80 price target for Bioventus, keeping it steady overall as minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions leave the valuation view essentially unchanged. What's in the News Bioventus Inc.ナラティブ更新 • Apr 03
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have revised their price target for Bioventus slightly lower from $15.00 to $14.80, reflecting updated fair value and discount rate assumptions while maintaining similar views on revenue growth, profit margin and future P/E expectations. What's in the News Bioventus Inc.ナラティブ更新 • Mar 19
BVS: 2026 Net Sales Guidance And Margin Outlook Will Support Further Upside
Analysts have adjusted their price target on Bioventus to $15.00 from $14.50, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that collectively support a slightly higher valuation. What's in the News Bioventus issued earnings guidance for 2026, setting expected net sales in a range of $600 million to $610 million.ナラティブ更新 • Mar 05
BVS: Refined Assumptions And 2026 Outlook Will Support Further Upside Potential
Analysts have adjusted their price target on Bioventus slightly lower from $15.00 to $14.50, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Bioventus issued earnings guidance for 2026, with expected net sales of $600 million to $610 million.
ナラティブ更新 • Feb 19
BVS: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their Bioventus price target to $13.00 from $7.00, reflecting updated views on fair value, discount rate assumptions, revenue growth expectations, profit margin outlook and future P/E multiples. Valuation Changes Fair Value: revised to $13.00 from $7.00, indicating a higher assessed equity value per share.ナラティブ更新 • Feb 05
BVS: Fine Tuned Assumptions Will Support Further Upside Potential
Analysts have nudged their price target on Bioventus to US$15.00, a modest change that reflects fine tuning to inputs such as the discount rate, long term revenue growth, profit margin assumptions, and expected future P/E rather than a shift in their overall view of the company. Valuation Changes Fair Value: Maintained at US$15.00 per share, with no change in the overall valuation output.ナラティブ更新 • Jan 22
BVS: Reaffirmed 2025 Guidance And Stable Assumptions Will Support Further Upside
Analysts have kept their fair value estimate for Bioventus unchanged at US$15.00, with only slight tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This signals a broadly steady view of the stock's risk and return profile.ナラティブ更新 • Jan 07
BVS: Reaffirmed 2025 Guidance Will Support Ongoing Upside Potential
Analysts have kept their fair value estimate for Bioventus steady at US$15.00, citing only very small tweaks to inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions that do not materially change their overall view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2025, signaling no change to its previously communicated outlook.ナラティブ更新 • Dec 20
BVS: Reaffirmed 2025 Earnings Guidance Will Support Continued Upside Potential
Analysts have nudged their price target on Bioventus slightly higher to reflect modestly stronger revenue growth expectations and a marginally lower discount rate, while keeping fair value unchanged at approximately $15.00 per share. What's in the News Bioventus reaffirmed its full year 2025 earnings guidance, signaling management confidence in the current strategic and operating plan (company guidance).ナラティブ更新 • Dec 06
BVS: Earnings Guidance Will Support Continued Upside Potential In Shares
Analysts have modestly raised their price target on Bioventus to approximately $15.00 per share from about $15.00 per share, reflecting slightly lower perceived risk, stable long term growth expectations, and marginally improved profitability and valuation assumptions. What's in the News Bioventus reaffirmed its 2025 earnings guidance, projecting net sales between $560 million and $570 million.分析記事 • Nov 26
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...ナラティブ更新 • Nov 22
BVS: Earnings Guidance Is Expected To Drive Share Price Higher
Analysts have updated their price target for Bioventus, raising it modestly from $14.67 to $15.00 per share. This change reflects improved revenue growth expectations, despite a slightly higher discount rate and lower projected profit margin.ナラティブ更新 • Nov 03
BVS: Net Sales Guidance Will Sustain Bullish Outlook Into 2025
Analysts have slightly raised their price target for Bioventus to $14.67 per share, citing minor updates to the company's discount rate and future price-to-earnings assumptions. What's in the News Bioventus Inc.ナラティブ更新 • Oct 20
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have modestly raised their price target for Bioventus, increasing it by $0.00 to $14.67. They cited slight adjustments to their discount rate and future price-to-earnings assumptions.ナラティブ更新 • Oct 05
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook. What's in the News Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million.分析記事 • Aug 14
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative
NasdaqGS:BVS 1 Year Share Price vs Fair Value Explore Bioventus's Fair Values from the Community and select yours...分析記事 • Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...新しいナラティブ • May 30
Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets
Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.分析記事 • May 07
Is Bioventus (NASDAQ:BVS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Mar 08
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues
Bioventus Inc.'s ( NASDAQ:BVS ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy right now...Seeking Alpha • Jan 05
Bioventus: Amply Rewarded For Recent Progress
Summary The stock of medical device concern Bioventus has roughly doubled over the past year, but has lost momentum recently. Management has done a commendable job in recent years in reducing debt and leverage ratios, and profits have rebounded significantly. What's ahead for Bioventus in 2025? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 12
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Summary Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE and EXOGEN. Despite positive performance, high debt and tough competition could impact future profits and valuation. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 27 2026 | n/a | n/a | US$54m |
| Mar 28 2026 | n/a | n/a | US$28m |
| Dec 31 2025 | US$4m | US$824k | US$23m |
| Sep 27 2025 | n/a | n/a | US$10m |
| Jun 28 2025 | n/a | n/a | -US$731k |
| Mar 29 2025 | n/a | n/a | -US$34m |
| Dec 31 2024 | US$6m | US$780k | -US$36m |
報酬と市場: Robの 総報酬 ($USD 4.30M ) は、 US市場 ($USD 5.15M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Robの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Rob Claypoole (54 yo)
2.6yrs
在職期間
US$4,299,108
報酬
Mr. Robert E. Claypoole, also known as Rob, is President, Chief Executive Officer and Director of Bioventus Inc. from January 10, 2024. He was Executive Vice President and President, U.S for Mlnlycke Healt...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 2.6yrs | US$4.30m | 0.20% $ 2.4m | |
| Senior VP & CFO | 4.4yrs | US$1.90m | 0.26% $ 3.1m | |
| Senior VP | 9yrs | US$1.41m | 0.22% $ 2.7m | |
| Senior Vice President of Operations | 2.8yrs | データなし | データなし | |
| Vice President of Investor Relations & Treasurer | no data | データなし | データなし | |
| Senior VP & Chief Compliance Officer | 6yrs | データなし | 0.094% $ 1.1m | |
| Senior VP & Chief Human Resources Officer | 3.3yrs | データなし | データなし | |
| Senior VP & GM of Surgical | 1.7yrs | データなし | データなし |
3.3yrs
平均在職期間
60.5yo
平均年齢
経験豊富な経営陣: BVSの経営陣は 経験豊富 であると考えられます ( 3.3年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 2.6yrs | US$4.30m | 0.20% $ 2.4m | |
| Independent Director | 5.9yrs | US$275.00k | 0.22% $ 2.6m | |
| Independent Director | 3.6yrs | US$290.00k | 0.16% $ 2.0m | |
| Independent Director | 5.9yrs | US$215.00k | 0.17% $ 2.1m | |
| Independent Chairman of the Board | 5.9yrs | US$380.00k | 0.44% $ 5.2m | |
| Independent Director | 5.9yrs | US$277.50k | 0.17% $ 2.1m | |
| Independent Director | 5.9yrs | US$300.00k | 0.20% $ 2.4m | |
| Independent Director | 5.1yrs | US$290.00k | 0.16% $ 2.0m | |
| Independent Director | 5.9yrs | US$245.00k | 0.064% $ 774.3k | |
| Independent Director | 4.8yrs | US$282.50k | 0.16% $ 1.9m | |
| Independent Director | 4.6yrs | US$280.00k | 0.11% $ 1.4m | |
| Independent Director | less than a year | データなし | データなし |
5.5yrs
平均在職期間
59.5yo
平均年齢
経験豊富なボード: BVSの 取締役会 は 経験豊富 であると考えられます ( 5.5年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/19 16:42 |
| 終値 | 2026/08/19 00:00 |
| 収益 | 2026/06/27 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Bioventus Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Kyle Rose | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |